Please note: The information displayed on this page might be outdated.
Immatics NV: Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Address:
Paul-Ehrlich-Str. 15
Tübingen, 72076
Germany

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Harpreet Singh, PhD
Immatics Biotechnologies GmbH , CEO
Harpreet co-founded Immatics in 2000 to translate pioneering scientific discoveries in immunology into highly innovative immunotherapies to impact the lives of cancer patients. Since the foundation, he has served as Managing Director and Chief Scientific Officer, helping to grow the Company from a start-up to a leading biotech player in the field of immuno-oncology. Harpreet has played a leadership role in raising more than US$200m of venture capital funding over several financing rounds. In 2014, Harpreet became President & CEO of Immatics US, overseeing all operations of Immatics in Houston, Texas to develop next-generation Adoptive Cell Therapies (ACT). He led the team that achieved a $20m CPRIT grant by the State of Texas. Harpreet was awarded "Private Company CEO of the Year" at the Lifestars Awards 2018 (in association with Jefferies), in recognition of his achievements. In 2019, Harpreet became CEO of Immatics Biotechnologies. Harpreet is the inventor on numerous granted patents and patent applications and co-author of numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Lancet Oncology. A scholar of Prof. Hans-Georg Rammensee, Harpreet completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.

Upcoming Company Event Participation

2020 Wall Street "On Tap"

Virtual, October 20, 2020

Top 10 Holders of Immatics N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Nantahala Capital Management LLC 3.75 2,360,742 23.91 Stakes 7/31/20
The Vanguard Group, Inc. 0.51 320,005 3.24 Funds 8/31/20

Top 10 Holders of Immatics N.V. Warrant 2020-01.07.25 on Immatics

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Jennison Associates LLC 0.00 278,909 2.83 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.